SG11202107306WA - Encapsulated glycolipid antigens for treatment of neoplastic diseases - Google Patents
Encapsulated glycolipid antigens for treatment of neoplastic diseasesInfo
- Publication number
- SG11202107306WA SG11202107306WA SG11202107306WA SG11202107306WA SG11202107306WA SG 11202107306W A SG11202107306W A SG 11202107306WA SG 11202107306W A SG11202107306W A SG 11202107306WA SG 11202107306W A SG11202107306W A SG 11202107306WA SG 11202107306W A SG11202107306W A SG 11202107306WA
- Authority
- SG
- Singapore
- Prior art keywords
- encapsulated
- treatment
- neoplastic diseases
- glycolipid antigens
- glycolipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788257P | 2019-01-04 | 2019-01-04 | |
| PCT/IB2020/050063 WO2020141495A1 (en) | 2019-01-04 | 2020-01-06 | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107306WA true SG11202107306WA (en) | 2021-08-30 |
Family
ID=71407387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107306WA SG11202107306WA (en) | 2019-01-04 | 2020-01-06 | Encapsulated glycolipid antigens for treatment of neoplastic diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12337033B2 (https=) |
| EP (1) | EP3906053A4 (https=) |
| JP (1) | JP7548911B2 (https=) |
| CN (1) | CN113507936A (https=) |
| AU (1) | AU2020205040A1 (https=) |
| CA (1) | CA3125702A1 (https=) |
| SG (1) | SG11202107306WA (https=) |
| WO (1) | WO2020141495A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106999444B (zh) * | 2014-10-03 | 2023-12-12 | 安吉尼科分子传输公司 | 完整的细菌衍生的囊泡对小分子化合物的增强装载 |
| CN121285390A (zh) * | 2023-04-17 | 2026-01-06 | 安吉尼科分子传输公司 | 用于递送α-半乳糖神经酰胺化合物的组合物和方法 |
| EP4656648A1 (en) * | 2024-05-31 | 2025-12-03 | Consejo Superior De Investigaciones Científicas | Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747002B2 (en) | 1999-05-11 | 2004-06-08 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| ATE541940T1 (de) | 2001-10-15 | 2012-02-15 | Engeneic Molecular Delivery Pty Ltd | Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo |
| CA2517027A1 (en) | 2002-02-25 | 2003-09-04 | Vaxiion Therapeutics, Inc. | Minicell compositions and methods |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| CN101954095B (zh) | 2003-12-09 | 2013-03-13 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
| EP1718338B1 (en) | 2004-02-02 | 2015-05-06 | EnGeneIC Molecular Delivery Pty Ltd. | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP2386640B1 (en) | 2004-08-26 | 2015-01-28 | EnGeneIC Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| US9878043B2 (en) | 2006-06-23 | 2018-01-30 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| DK2865755T3 (en) | 2007-03-30 | 2017-05-15 | Engeneic Molecular Delivery Pty Ltd | BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA |
| ES2720659T3 (es) | 2011-02-15 | 2019-07-23 | Vaxiion Therapeutics Llc | Composiciones terapéuticas y métodos para la administración dirigida, mediante minicélulas bacterianas, de moléculas bioactivas basadas en moléculas dirigidas que contienen Fc y anticuerpos |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| US8591963B2 (en) | 2011-10-06 | 2013-11-26 | Jose Luis MENDOZA | Direct application pet odor eliminator |
| US9365496B2 (en) | 2011-11-30 | 2016-06-14 | Ludwig Institute For Cancer Research | iNKT cell modulators and methods of using the same |
| US20150283235A1 (en) | 2012-11-05 | 2015-10-08 | Regimmune Corporation | Immune-tolerance inducer |
| SG11201602429QA (en) | 2013-10-04 | 2016-04-28 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
| WO2015116775A1 (en) | 2014-01-30 | 2015-08-06 | Trudeau Institute | Nanoparticles for immune stimulation |
| US11167008B2 (en) | 2016-11-23 | 2021-11-09 | Vaxiion Therapeutics, Llc | Immunomodulatory and oncolytic minicells and methods of use |
| JP2021532106A (ja) | 2018-07-23 | 2021-11-25 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
-
2020
- 2020-01-06 CN CN202080017961.7A patent/CN113507936A/zh active Pending
- 2020-01-06 EP EP20735988.6A patent/EP3906053A4/en active Pending
- 2020-01-06 SG SG11202107306WA patent/SG11202107306WA/en unknown
- 2020-01-06 AU AU2020205040A patent/AU2020205040A1/en active Pending
- 2020-01-06 US US17/420,624 patent/US12337033B2/en active Active
- 2020-01-06 CA CA3125702A patent/CA3125702A1/en active Pending
- 2020-01-06 JP JP2021539364A patent/JP7548911B2/ja active Active
- 2020-01-06 WO PCT/IB2020/050063 patent/WO2020141495A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US12337033B2 (en) | 2025-06-24 |
| AU2020205040A1 (en) | 2021-08-12 |
| WO2020141495A1 (en) | 2020-07-09 |
| EP3906053A4 (en) | 2023-01-11 |
| JP2022516347A (ja) | 2022-02-25 |
| US20220105177A1 (en) | 2022-04-07 |
| JP7548911B2 (ja) | 2024-09-10 |
| CA3125702A1 (en) | 2020-07-09 |
| CN113507936A (zh) | 2021-10-15 |
| EP3906053A1 (en) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288523A (en) | Compounds for the treatment of pd-l1 diseases | |
| IL291735A (en) | Heteroarylbiphenylamines for the treatment of pd-l1 diseases | |
| IL291642A (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| IL274766A (en) | Human anti-LIV1 antibodies for the treatment of breast cancer | |
| IL278041A (en) | Bezumab formulations with a buffer for use in the treatment of diseases | |
| ZA202104357B (en) | Monoclonal antibodies against the beta chain region of human trbv9 | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| SG11202006374VA (en) | Treatment of demyelinating diseases | |
| GB202012331D0 (en) | Therapeutic antibodies | |
| IL285807A (en) | Immunotherapy for cancer treatment | |
| IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
| SG11202107306WA (en) | Encapsulated glycolipid antigens for treatment of neoplastic diseases | |
| IL271488A (en) | Chimeric antibodies for the treatment of diseases characterized by amyloid deposition | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| IL289842A (en) | Human anti-liv1 antibodies for cancer therapy | |
| IL282361A (en) | Treatment for neurological diseases | |
| PL3603621T3 (pl) | Liposomy do leczenia chorób oczu | |
| SG11202108636SA (en) | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | |
| PT3761982T (pt) | Utilização da nalfurafina no tratamento de doenças desmielinizantes | |
| SG11202106129RA (en) | Novel approach for treatment of cancer using immunomodulation | |
| SG11202106912WA (en) | Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases | |
| GB201801466D0 (en) | Preparation for treatment of wounds | |
| GB202108677D0 (en) | Therapeutic antibodies | |
| GB201909438D0 (en) | Treatment of diseases |